Ralph Baisden
Family · Simpsonville, SCNPI 1275634784
Payments from drug & device makers
Across 82 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$246
- Novo Nordisk$206
- Boston Scientific$148
- Pfizer$76
- GSK$72
- AstraZeneca$64
- plus $515 from 14 others
What the payments were for
- Food & beverage$1,328100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 15 | $246 |
| Novo Nordisk | 17 | $206 |
| Boston Scientific | 1 | $148 |
| Pfizer | 5 | $76 |
| GSK | 5 | $72 |
| AstraZeneca | 5 | $64 |
| Boehringer Ingelheim | 4 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $55 |
| Johnson & Johnson | 4 | $55 |
| Lilly USA, LLC | 3 | $46 |
| Dexcom, Inc. | 3 | $44 |
| Amgen | 2 | $43 |
| AbbVie | 3 | $41 |
| Merck | 3 | $38 |
| Bayer | 1 | $36 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Eisai Inc. | 2 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,328 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,495 |
| SynthroidLevothyroxine Sodium | 11 | $724 |
| Rosuvastatin Calcium | 25 | $530 |
| Gabapentin | 13 | $298 |
| Montelukast Sodium | 23 | $278 |
| Levothyroxine Sodium | 21 | $234 |
| Lisinopril | 36 | $189 |
| Omeprazole | 22 | $186 |
| Pravastatin Sodium | 14 | $184 |
| Atorvastatin Calcium | 45 | $161 |
| Metoprolol Succinate | 18 | $154 |
| Allopurinol | 12 | $151 |
| Amlodipine Besylate | 42 | $141 |
| Pantoprazole Sodium | 14 | $134 |
| Citalopram HbrCitalopram Hydrobromide | 13 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $72 | $10,49516 claims |
| AbbVieSynthroid | $41 | $72411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.
Other family in Simpsonville
- Doris ReidSimpsonville$25K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.